CoChat

A pilot, open‐label, 8‐week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression

Soczynska, Joanna K, Kennedy, Sidney H, Alsuwaidan, Mohammad, Mansur, Rodrigo B, Li, Madeline, McAndrews, Mary Pat, Brietzke, Elisa, Woldeyohannes, Hanna O, Taylor, Valerie H, McIntyre, Roger S · 2017 · Bipolar Disorders
Cited by 49

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Objectives: The objectives of the study were to determine if adjunctive minocycline mitigates depressive symptom severity and improves cognitive function in individuals with bipolar I/II disorder (BD). The study also aimed to determine if changes in depressive and/or cognitive symptoms over the course of treatment were associated with changes in circulating inflammatory cytokine levels. Methods: A total of 29 (intention‐to‐treat: n=27) adults meeting DSM‐IV‐TR criteria for a major depressive episode as part of bipolar I or II disorder (i.e. Hamilton Depression Rating Scale 17‐item [HAMD‐17] ≥20) were enrolled in an 8‐week, open‐label study with adjunctive minocycline (100 mg bid). The primary outcome measure was the Montgomery−Åsberg Depression Rating Scale (MADRS). The HAMD‐17, Clinical Global Impression‐Severity (CGI‐S), cognitive test composite scores and plasma cytokines were secondary outcome measures. Plasma cytokines were measured with the 30 V‐Plex Immunoassay from Meso Scale Discovery. Results: Adjunctive minocycline was associated with a reduction in depressive symptom severity from baseline to week 8 on the MADRS (P<.001, d=0.835), HAMD‐17 (P<.001, d=0.949) and CGI‐S (P<.001, d=1.09). Improvement in psychomotor speed, but not verbal memory or executive function, was observed only amongst individuals exhibiting a reduction in depression severity (P=.007, d=0.826). Levels of interleukin (IL)‐12/23p40 (P=.002) were increased, while levels of IL‐12p70 (P=.001) and C‐C motif chemokine ligand 26 (CCL26) (P<.001) were reduced from baseline to week 8. A reduction in CCL 26 levels was associated with a less favourable treatment response (P<.001). Conclusions: Results from the pilot study suggest that adjunctive minocycline may exert antidepressant effects in individuals with bipolar depression, possibly by targeting inflammatory cytokines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bdi.12496

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 49

Metadata

Authors
Soczynska, J. K., Kennedy, S. H., Alsuwaidan, M., Mansur, R. B., Li, M., McAndrews, M. P., Brietzke, E., Woldeyohannes, H. O., Taylor, V. H., & McIntyre, R. S.
Venue
Bipolar Disorders
Publisher
Wiley
Published
2017-05
Volume
19
Issue
3
Pages
198-213
ISSN
  • 1398-5647 (ISSN-L)
  • 1399-5618
OpenAlex
W2623849798
Cited by
49
References
28
FWCI
5.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A pilot, open‐label, 8‐week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. https://app.cochat.ai/papers/10.1111/bdi.12496
The paper
Soczynska, J. K., Kennedy, S. H., Alsuwaidan, M., Mansur, R. B., Li, M., McAndrews, M. P., Brietzke, E., Woldeyohannes, H. O., Taylor, V. H., & McIntyre, R. S. (2017). A pilot, open‐label, 8‐week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disorders. https://doi.org/10.1111/bdi.12496

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.